Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00227_DB00661_nanopub.RAyFXvna-Uf-0jUrmn6fP-VLF_bKouHd4ect8LcJqc_h0#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00227_DB00661 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00227_DB00661 label "DDI between Lovastatin and Verapamil - Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Lovastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Lovastatin if Verapamil is initiated, discontinued or dose changed. [drugbank_resource:DB00227_DB00661]" assertion.
- drugbank_resource:DB00227_DB00661 identifier "drugbank_resource:DB00227_DB00661" assertion.
- drugbank_resource:DB00227_DB00661 title "DDI between Lovastatin and Verapamil - Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Lovastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Lovastatin if Verapamil is initiated, discontinued or dose changed." assertion.
- drugbank:DB00227 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00227_DB00661 assertion.
- drugbank:DB00661 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00227_DB00661 assertion.